Karolinska University Hospital

The Department of Pelvic Cancer at Karolinska University Hospital conducts extensive research on solid tumours and haematologic malignancies, aiming to evaluate new therapeutic combinations and improve survival outcomes.

• Advanced epithelial ovarian cancer
• Advanced or recurrent endometrial cancer
• Renal cell carcinoma
• Breast cancer
• Prostate cancer
• Melanoma
• Gastrointestinal stromal tumour
• Neuroblastoma
• Liposarcoma
• Non‑small cell lung cancer
• Pancreatic ductal adenocarcinoma
• Testicular germ‑cell tumours

Across more than 70 trials, investigators explore targeted agents, immunotherapies and precision‑medicine approaches to enhance treatment effectiveness.

Research focuses on ovarian, endometrial and cervical malignancies as well as conditions such as preeclampsia, seeking to refine surgical timing and adjuvant strategies.

• Advanced epithelial ovarian cancer
• Endometrial cancer
• Cervical cancer
• Preeclampsia
• Endometriosis‑related pelvic pain

Trials evaluate peri‑operative interventions and novel hormonal regimens to improve reproductive health and cancer outcomes.

The site investigates autoimmune skin conditions and inflammatory myopathies, testing biologics and small molecules to reduce disease activity.

• Cutaneous lupus erythematosus
• Dermatomyositis
• Polymyositis
• Alopecia areata
• Atopic dermatitis
• Idiopathic inflammatory myopathies

Efforts aim to modulate immune pathways and achieve durable remission with fewer side effects.

Clinical studies address heart failure, atherosclerotic disease and stroke prevention, evaluating novel oral agents and device‑based diagnostics.

• Chronic heart failure with reduced ejection fraction
• Atherosclerotic cardiovascular disease
• Ischemic stroke
• Atrial fibrillation
• Type 2 diabetes

The goal is to lower mortality and hospitalisation by integrating cardioprotective therapies.

Investigations target gastrointestinal cancers and inflammatory bowel disease, seeking better chemotherapeutic schedules and biomarker‑guided treatment.

• Gastric cancer
• Gastroesophageal junction carcinoma
• Crohn’s disease
• Pancreatic ductal adenocarcinoma
• Colorectal cancer

Precision diagnostics such as genetic phenotyping guide therapeutic choices.

Trials explore Parkinson’s disease, stroke recovery and brain tumour imaging, aiming to preserve cognition and motor function.

• Parkinson’s disease
• Acute ischemic stroke
• Brain tumour
• Neuroblastoma (pediatric CNS involvement)
• Cognitive decline after radiotherapy

Advanced imaging with PET/CT and neuroprotective agents are central to these studies.

The department conducts studies on B‑cell lymphomas, acute leukaemias and chronic lymphocytic leukaemia, focusing on antibody‑drug conjugates and emerging cellular therapies.

• Diffuse large B‑cell lymphoma
• Follicular lymphoma
• Acute lymphoblastic leukaemia (pediatric)
• Chronic lymphocytic leukaemia
• Mature aggressive B‑cell lymphoma

Therapies aim to increase overall response rates while minimizing toxicity.

Special attention is given to rare sarcomas, germ‑cell tumours and paediatric solid tumours, testing radioligand therapy and targeted inhibitors.

• Dedifferentiated liposarcoma
• Malignant extragonadal germ‑cell tumour
• High‑risk neuroblastoma
• Gastrointestinal stromal tumour
• Pediatric B‑cell lymphoma

Safety and long‑term outcomes are evaluated through longitudinal follow‑up.